NKTX - Nkarta, Inc.
2.77
-0.060 -2.166%
Share volume: 484,858
Last Updated: 04-28-2026
Pharmaceutical Products/Pharmaceutical Preparations:
-0.12%
PREVIOUS CLOSE
CHG
CHG%
$2.83
-0.06
-0.02%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-09-2024 | 08-13-2024 | 11-07-2024 | 03-26-2025 | 05-14-2025 | 11-10-2025 | 03-25-2026 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 32.762 M | 30.715 M | 33.794 M | 30.923 M | 36.564 M | 27.286 M | 30.961 M | |
| Selling general and admin | 7.525 M | 7.585 M | 8.544 M | 7.796 M | 12.392 M | 7.088 M | 5.680 M | |
| Research and development | 25.237 M | 23.130 M | 25.250 M | 23.127 M | 24.172 M | 20.198 M | 25.281 M | |
| Total expenses | 32.762 M | 30.715 M | 33.794 M | 30.923 M | 36.564 M | 27.286 M | 30.961 M | |
| -6.25% | 10.02% | -8.50% | 18.24% | -25.37% | 13.47% | |||
| Operating income | -32.762 M | -30.715 M | -33.794 M | -30.923 M | -36.564 M | -27.286 M | -30.961 M | |
| Ebit | -32.764 M | -30.717 M | -33.797 M | -30.829 M | -36.359 M | -25.567 M | -30.705 M | |
| Pretax income | -29.518 M | -24.993 M | -28.344 M | -25.935 M | -31.983 M | -21.715 M | -27.409 M | |
| -15.33% | 13.41% | -8.50% | 23.32% | -32.10% | 26.22% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -29.518 M | -24.993 M | -28.344 M | -25.935 M | -31.983 M | -21.715 M | -27.409 M | |
| 15.33% | -13.41% | 8.50% | -23.32% | 32.10% | -26.22% |